Subscribe to stay informed!
Malvern-based Endo Pharmaceuticals has agreed to acquire BioSpecifics Technologies, a 20-year-old company based in Wilmington, for around $658 million, writes Joseph DiStefano…
Before we send you to this site, please subscribe to our daily newsletter.